Literature DB >> 11559720

Primary chemotherapy for operable breast cancer: incidence and prognostic significance of ipsilateral breast tumor recurrence after breast-conserving surgery.

R Rouzier1, J M Extra, M Carton, M C Falcou, A Vincent-Salomon, A Fourquet, P Pouillart, E Bourstyn.   

Abstract

PURPOSE: To determine the incidence and the prognostic value of ipsilateral breast tumor recurrence (IBTR) in patients treated with primary chemotherapy and breast-conserving surgery. PATIENTS AND METHODS: Between January 1985 and December 1994, 257 patients with invasive T1 to T3 breast carcinoma were treated with primary chemotherapy, lumpectomy, and radiation therapy. The median follow-up time was 93 months. To evaluate the role of IBTR in metastase-free survival, a Cox regression multivariate analysis was performed using IBTR as a time-dependent covariate.
RESULTS: The IBTR rates were 16% (+/- 2.4%) at 5 years and 21.5% (+/- 3.2%) at 10 years. Multivariate analysis showed that the probability of local control was decreased by the following independent factors: age < or = 40 years, excision margin < or = 2 mm, S-phase fraction more than 4%, and clinical tumor size more than 2 cm at the time of surgery. In patients with excision margins of more than 2 mm, the IBTR rates were 12.7% at 5 years and 17% at 10 years. Nodal status, age < or = 40 years, and negative estrogen receptor status were predictors of distant disease in the Cox multivariate model with fixed covariates. The contribution of IBTR was highly significant (relative risk = 5.34) when added to the model, whereas age < or = 40 years was no longer significant. After IBTR, 31.4% (+/- 7.0%) of patients developed metastases at 2 years and 59.7% (+/- 8.1%) at 5 years. Skin involvement, size at initial surgery, and estrogen receptor status were predictors of metastases after IBTR.
CONCLUSION: IBTR is a strong predictor for distant metastases. There are implications for conservative surgery after downstaging of the tumor and therapy at the time of IBTR.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11559720     DOI: 10.1200/JCO.2001.19.18.3828

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  32 in total

1.  Locoregional risk assessment after neoadjuvant chemotherapy in patients with primary breast cancer: clinical utility of the CPS + EG score.

Authors:  Laura L Michel; Laura Sommer; Rosa González Silos; Justo Lorenzo Bermejo; Alexandra von Au; Julia Seitz; André Hennigs; Katharina Smetanay; Michael Golatta; Jörg Heil; Florian Schütz; Christof Sohn; Andreas Schneeweiss; Frederik Marmé
Journal:  Breast Cancer Res Treat       Date:  2019-06-24       Impact factor: 4.872

Review 2.  Recent developments in breast-conserving surgery for breast cancer patients.

Authors:  F Fitzal; O Riedl; R Jakesz
Journal:  Langenbecks Arch Surg       Date:  2008-09-10       Impact factor: 3.445

3.  Surgical Considerations After Neoadjuvant Chemotherapy: Breast Conservation Therapy.

Authors:  Thomas A Buchholz; Elizabeth A Mittendorf; Kelly K Hunt
Journal:  J Natl Cancer Inst Monogr       Date:  2015-05

4.  Nanolipid carrier-based thermoreversible gel for localized delivery of docetaxel to breast cancer.

Authors:  Tanya Vohra; Inderpreet Kaur; Hemraj Heer; Rayasa Ramachandra Murthy
Journal:  Cancer Nanotechnol       Date:  2013-03-16

Review 5.  Local Recurrence after Breast-Conserving Surgery and Mastectomy Following Neoadjuvant Chemotherapy for Locally Advanced Breast Cancer - a Meta-Analysis.

Authors:  Xiaodong Zhou; Yujie Li
Journal:  Breast Care (Basel)       Date:  2016-10-14       Impact factor: 2.860

6.  Classification of ipsilateral breast tumor recurrences after breast conservation therapy can predict patient prognosis and facilitate treatment planning.

Authors:  Min Yi; Thomas A Buchholz; Funda Meric-Bernstam; Isabelle Bedrosian; Rosa F Hwang; Merrick I Ross; Henry M Kuerer; Sheng Luo; Ana M Gonzalez-Angulo; Aman U Buzdar; W Fraser Symmans; Barry W Feig; Anthony Lucci; Eugene H Huang; Kelly K Hunt
Journal:  Ann Surg       Date:  2011-03       Impact factor: 12.969

7.  Evaluation of the MD Anderson Prognostic Index for local-regional recurrence after breast conserving therapy in patients receiving neoadjuvant chemotherapy.

Authors:  Catherine L Akay; Funda Meric-Bernstam; Kelly K Hunt; Elizabeth G Grubbs; Isabelle Bedrosian; Susan L Tucker; Henry M Kuerer; Karen E Hoffman; Gildy V Babiera; Eric A Strom; Thomas A Buchholz; Elizabeth A Mittendorf
Journal:  Ann Surg Oncol       Date:  2011-08-23       Impact factor: 5.344

8.  A Bayesian model for misclassified binary outcomes and correlated survival data with applications to breast cancer.

Authors:  Sheng Luo; Min Yi; Xuelin Huang; Kelly K Hunt
Journal:  Stat Med       Date:  2012-09-21       Impact factor: 2.373

9.  Predictors of recurrence in breast cancer patients with a pathologic complete response after neoadjuvant chemotherapy.

Authors:  M Tanioka; C Shimizu; K Yonemori; K Yoshimura; K Tamura; T Kouno; M Ando; N Katsumata; H Tsuda; T Kinoshita; Y Fujiwara
Journal:  Br J Cancer       Date:  2010-07-06       Impact factor: 7.640

10.  State of the art of neoadjuvant chemotherapy in breast cancer: rationale, results and recent developments.

Authors:  Arnd Honig; Lorenz Rieger; Marc Sutterlin; Diethelm Wallwiener; Johannes Dietl; Erich-Franz Solomayer
Journal:  Ger Med Sci       Date:  2005-09-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.